RNA vaccine against SARS-CoV-2 variants
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
1. A composition comprising
(a) an mRNA comprising:
(i) at least one coding sequence encoding a SARS-CoV-2 spike protein (S) at least 90% identical to SEQ ID NO: 10 that is a pre-fusion stabilized spike protein (S_stab) comprising K986P and V987P stabilizing mutations and 10 or more of the following substitutions relative to SEQ ID NO: 10: A67V, H69del, V70del, T951, G142D, V143del, Y144del, Y145del, N211del, L2121, ins214EPE, G339D, 5371L, S373P, S375F, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L981F, and
(ii) at least one heterologous untranslated region (UTR); and
(b) at least one pharmaceutically acceptable carrier,
wherein the mRNA is complexed or associated with a lipid nanoparticle (LNP) and wherein the LNP comprises:
(i) at least one cationic lipid;
(ii) at least one neutral lipid;
(iii) at least one steroid or steroid analogue; and
(iv) at least one PEG-lipid,
wherein (i) to (iv) are in a molar ratio of about 20-60% of the at least one cationic lipid, 5-25% of the at least one neutral lipid, 25-55% of the at least one steroid or steroid analogue, and 0.5-5% of the at least one PEG-lipid.
2. A composition comprising
(a) an mRNA comprising:
(i) at least one coding sequence encoding a SARS-CoV-2 spike protein (S) at least 95% identical to SEQ ID NO: 10 and is a pre-fusion stabilized spike protein (S_stab) comprising K986P and V987P stabilizing mutations and T19R, F157del, R158del, L452R, T478K, D614G, P681R and D950N amino acid substitutions relative to SEQ ID NO: 10, and
(ii) at least one heterologous untranslated region (UTR); and
(b) at least one pharmaceutically acceptable carrier,
wherein the mRNA is complexed or associated with a lipid nanoparticle (LNP) and wherein the LNP comprises:
(i) at least one cationic lipid;
(ii) at least one neutral lipid;
(iii) at least one steroid or steroid analogue; and
(iv) at least one PEG-lipid,
wherein (i) to (iv) are in a molar ratio of about 20-60% of the at least one cationic lipid, 5-25% of the at least one neutral lipid, 25-55% of the at least one steroid or steroid analogue, and 0.5-15% of the at least one PEG-lipid.
3. A composition comprising
(a) an mRNA comprising:
(i) at least one coding sequence encoding a SARS-CoV-2 spike protein (S) at least 95% identical to SEQ ID NO: 10 that is a pre-fusion stabilized spike protein (S_stab) comprising K986P and V987P stabilizing mutations and 10 or more of the following substitutions relative to SEQ ID NO: 10: A67V, H69del, V70del, T951, G142D, V143del, Y144del, Y145del, N211del, L2121, ins214EPE, G339D, 5371L, S373P, S375F, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K and L981F, and
(ii) at least one heterologous untranslated region (UTR);
(b) an mRNA comprising:
(i) at least one coding sequence encoding a SARS-CoV-2 spike protein (S) at least 95% identical to SEQ ID NO: 10 and is a pre-fusion stabilized spike protein (S_stab) comprising K986P and V987P stabilizing mutations and T19R, F157del, R158del, L452R, T478K, D614G, P681R and D950N amino acid substitutions relative to SEQ ID NO: 10, and
(ii) at least one heterologous untranslated region (UTR); and
(c) at least one pharmaceutically acceptable carrier,
wherein the mRNA is complexed or associated with a lipid nanoparticle (LNP) and wherein the LNP comprises:
(i) at least one cationic lipid;
(ii) at least one neutral lipid;
(iii) at least one steroid or steroid analogue; and
(iv) at least one PEG-lipid,
wherein (i) to (iv) are in a molar ratio of about 20-60% of the at least one cationic lipid, 5-25% of the at least one neutral lipid, 25-55% of the at least one steroid or steroid analogue, and 0.5-5% of the at least one PEG-lipid.
4. The composition of claim 1 , wherein the mRNA comprises at least one poly(A) sequence comprising 30 to 200 adenosine nucleotides and a 5′-cap structure.
5. The composition of claim 1 , wherein the at least one coding sequence of the mRNA has a G/C content of at least about 50%.
6. The composition of claim 5 , wherein the at least one coding sequence of the mRNA has a G/C content of at least about 55%.
7. The composition of claim 1 , wherein the mRNA comprises a sequence at least 90% identical to SEQ ID NO: 28590.
8. The composition of claim 1 , wherein the at least one heterologous UTR is selected from at least one heterologous 5′-UTR and/or at least one heterologous 3′-UTR.
9. The composition of claim 8 , wherein the at least one heterologous 3′-UTR comprises or consists of a nucleic acid sequence derived from a 3′-UTR of a gene selected from PSMB3, ALB7, alpha-globin, CASP1, COX6B1, GNAS, NDUFA1 and RPS9; or
wherein the at least one heterologous 5′-UTR comprises or consists of a nucleic acid sequence derived from a 5′-UTR of a gene selected from HSD17B4, RPL32, ASAH1, ATP5A1, MP68, NDUFA4, NOSIP, RPL31, SLC7A3, TUBB4B and UBQLN2.
10. The composition of claim 1 , wherein the mRNA comprises at least one histone stem-loop.
11. The composition of claim 1 , wherein the mRNA comprises a nucleotide analog substitution.
12. The composition of claim 11 , wherein the mRNA comprises a pseudouridine or 1-methylpseudouridine substitution at a uridine position.
13. The composition of claim 1 , wherein the mRNA comprises a 1-methylpseudouridine substitution at a uridine position.
14. The composition of claim 1 , wherein the mRNA has an RNA integrity of at least about 50%.
15. The composition of claim 1 . wherein the mRNA is a purified mRNA that has been purified by reversed-phase high pressure liquid chromatography andior tangential flow filtration.
16. The composition of claim 15 , wherein the mRNA is a purified mRNA that has been purified by reversed-phase high pressure liquid chromatography and/or tangential flow filtration and comprises about 5%, 10%, or 20% less double stranded RNA side products as compared to an RNA that has not been purified with reversed-phase high pressure liquid chromatography and/or tangential flow filtration.
17. The composition of claim 1 , wherein the LNP comprises a cationic lipid according to formula III:
or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:
L 1 or L 2 is each independently —O(C═O)—, —(C═O)O—, —C(═O)—, —O—, —S(O) x —, —S—S—, —C(═O)S—, —SC(═O)—,
—NR a C(═O)—, —C(═O)NR a —, —NR a C(═O)NR a —, —OC(═O)NR a — or —NR a C(═O)O—;
G 1 and G 2 are each independently unsubstituted C 1 -C 12 alkylene or C 1 -C 12 alkenylene;
G 3 is C 1 -C 24 alkylene, C 1 -C 24 alkenylene, C 3 -C 8 cycloalkylene, or C 3 -C 8 cycloalkenylene;
R a is H or C 1 -C 12 alkyl;
R 1 and R 2 are each independently C 6 -C 24 alkyl or C 6 -C 24 alkenyl;
R 3 is H, OR 5 , CN, —C(═O)OR 4 , —OC(═O)R 4 or —NR 5 C(═O)R 4 ;
R 4 is C 1 -C 12 alkyl; and
R 5 is H or C 1 -C 6 alkyl.
18. The composition of claim 17 , wherein the LNP comprises:
(i) at least one neutral lipid comprising 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); and
(ii) at least one sterol comprising cholesterol.
19. The composition of claim 18 , wherein the mRNA comprises a sequence at least 90% identical to SEQ ID NO: 163.
20. The composition of claim 1 , further comprising a lyoprotectant.
21. The composition of claim 20 , wherein the lyoprotectant comprises sucrose.
22. The composition of claim 1 , wherein the composition comprises less than about 20% free mRNA.
23. The composition of claim 1 , wherein the LNP have a mean diameter of from about 60 nm to 200 nm.
24. The composition of claim 1 , wherein the composition has a lipid to RNA molar ratio (N/P ratio) of from about 2 to about 12.
25. The composition of claim 15 , wherein the composition has a lipid to RNA molar ratio (N/P ratio) of from about 2 to about 12.
26. A kit comprising the composition according to claim 1 and optionally comprising a liquid vehicle for solubilising, and, optionally, technical instructions providing information on administration and dosage for use.
27. A method of treating or preventing a disorder, wherein the method comprises applying or administering to a subject in need thereof the composition according to claim 1 .